Healthcare Industry News: Accuray
News Release - February 5, 2020
Studies Support Use of the Accuray TomoTherapy(R) System for Advanced Rectal Cancer to Improve Treatment Efficacy and Reduce Side EffectsSUNNYVALE, Calif., Feb. 5, 2020 -- (Healthcare Sales & Marketing Network) -- Accuray Incorporated (NASDAQ: ARAY) announced today that two new studies demonstrate the benefits of the TomoTherapy® System in the treatment of advanced rectal cancer. Radiotherapy, with or without chemotherapy, followed by surgery is the standard of care in the treatment of locally, advanced rectal cancer. However, radiation delivered to surrounding organs, such as the bowel and bladder, may lead to life-changing side effects, making it critically important for the radiation to be delivered with extreme accuracy and precision. The TomoTherapy platform, including the next-generation Radixact® System, is the only system available that is capable of helical radiation delivery — continuously delivering image-guided, intensity-modulated radiation therapy (IG-IMRT) from a full 360 degrees around the patient as the treatment table also moves — providing greater control of the radiation dose so it conforms precisely to the tumor and minimizes dose to healthy tissue.
Patients enrolled in the two studies received simultaneous daily radiation and a targeted radiation boost over a 25-day time period. The study investigators found that the TomoTherapy platform's unique architecture enabled the delivery of a high dose of radiation, directly to the tumor, through the integrated boost of radiation, while minimizing radiation to organs in close proximity to the targeted tumor. As a result, patients in the studies experienced improved treatment results and reduced side effects. These study outcomes compare favorably to conventional radiotherapy, based on results from other studies.
Novel treatment approach shows promising results
The clinical teams at Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland and the Clinica Luganese in Lugano, Switzerland, reported on their retrospective analysis of patients with advanced rectal cancer treated with TomoHelical™. The study titled, "Neoadjuvant chemoradiotherapy delivered with helical tomotherapy under daily image guidance for rectal cancer patients: efficacy and safety in a large, multi-institutional series," was published in the Journal of Cancer Research and Clinical Oncology, and found:
- Treatment with TomoHelical is safe, with low rates of severe toxicity
- Radiation delivered with helical TomoTherapy following daily imaging with the platform's integrated imaging capabilities allowed for the reduction of treatment margins around the tumor, so less normal tissue was irradiated. The authors highlight a "clear reduction in the rates of acute and late non-hematological toxicities" when compared to a randomized trial evaluating the use of 2D- or conformal 3D-RT techniques, published in the New England Journal of Medicine (NEJM)
- The four-year outcomes showed excellent local tumor control and disease-free survival rates of 88.4 percent and 74.6 percent, respectively
- A significantly higher rate of pathological complete response (pCR) was reported in the group of patients who received a simultaneous integrated boost compared to those who did not receive the boost. pCR is an indication of how well the treatment is working, with those patients achieving a pCR experiencing reduced rates of local recurrence and better overall survival
Targeted radiation boost helps maintain patient quality of life
In another study, clinicians at Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College in Beijing, People's Republic of China, published results of their advanced rectal cancer study titled, "Concomitant dose escalation with image-guided TomoTherapy® in locally advanced mid-low rectal cancer: a single-center study," in Cancer Management and Research. Highlights of the study include:
- The clinical team used TomoHelical™ to simultaneously deliver daily radiation treatments and a targeted radiation dose boost to the primary tumor, to improve outcomes and quality of life in patients with advanced rectal cancer
- TomoHelical treatment was able to significantly reduce the volume of the tumor, while minimizing dose to surrounding organs-at-risk. This enabled surgeons to perform sphincter-preserving surgery while removing the remaining tumor in 80.1 percent of patients in the study, thereby increasing the chance of maintaining normal bowel function and preserving quality of life
- Treatment resulted in positive outcomes with 95.5 percent of patients showing local tumor control and 70.9 percent exhibiting no signs of cancer five years after the radiation therapy procedure
- At the study authors' institution, the outcomes associated with TomoHelical treatment were superior to that with their non-dose-escalated conventional approach
"These most recent studies are a valuable addition to the available literature on the use of chemoradiation prior to surgery in the treatment of advanced rectal cancer. The treatment outcomes are extremely promising and may offer new hope to patients whose previous options were limited," said Fabienne Hirigoyenberry-Lanson, Ph.D., vice president global medical and scientific affairs, at Accuray. "The treatment regimens described in the studies reinforce the benefits of the unique capabilities of the TomoTherapy platform and what we would also expect to see with the Radixact® System. With TomoHelical mode, clinical teams were able to effectively and efficiently treat the rectal tumors while minimizing side effects and importantly, their potential impact on quality of life."
Accuray Incorporated (Nasdaq: ARAY) develops, manufactures and sells radiotherapy systems that are intended to make cancer treatments shorter, safer, personalized and more effective, ultimately enabling patients to live longer, better lives. Our radiation treatment delivery systems in combination with fully-integrated software solutions set the industry standard for precision and cover the full range of radiation therapy and radiosurgery procedures. For more information, please visit www.Accuray.com or follow us on Facebook, LinkedIn, Twitter and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to highly conformal radiation doses delivered with TomoHelical becoming the new standard of care for certain patients, expecting to see the benefits of the unique capabilities of the TomoTherapy platform in the Radixact System, clinical applications, clinical results, patient experiences and outcomes, and Accuray's leadership position in radiation oncology innovation and technologies. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products, including new product offerings and improvements; the company's ability to develop new products or improve existing products to meet customers' needs; the company's limited long-term clinical data supporting the safety and efficacy of its products, including product improvements, for certain users and such other risks identified under the heading "Risk Factors" in the company's quarterly report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on November 6, 2019, and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
1 Sauer R, et al: Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer. N Engl J Med. 2004 Oct 21;351(17):1731-40.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsHong Kong Sanatorium & Hospital Transforms Cancer Care in Asia with Treatment of First Patient Using the Accuray Radixact(R) System and ClearRT(TM) Helical Fan-Beam kVCT Imaging
Accuray Expands CyberKnife(R) System Versatility with Integration of RaySearch's RayStation Treatment Planning System
RayStation Latest Release, Now with Support for Accuray's CyberKnife(R) System